ChAbS

👏 Congratulations to GSK for FDA's Approval of Blenrep Combo for Relapsed Multiple Myeloma. The US FDA has approved GSK’s Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma after at least two prior treatments. In the phase III DREAMM-7 trial, the combination cut the risk of death by 51% and tripled progression-free survival versus a daratumumab-based regimen. Blenrep is the only anti-BCMA therapy available in community settings and will be launched under a streamlined REMS program to simplify patient access. GSK plans further studies in earlier treatment lines.   The ChAbS is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics (New official website: chabs.org). Antibody Therapeutics is the official journal of ChAbS, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI (Impact Factor: 4.5), PubMed and Scopus (CiteScore: 8.4). https://lnkd.in/gX4GrC7C

We are thrilled to share that Tubulis GmbH, a Munich‑based oncology biotech, has closed a €308 million Series C financing to accelerate development of its lead ADC (antibody‑drug conjugate) candidate, TUB‑040, and expand its broader pipeline. This round is reportedly the largest Series C ever raised by a European biotech and the largest for a private ADC developer globally. More information can be found here: https://lnkd.in/eHd33H7b The Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI (Impact Factor: 4.5), PubMed and Scopus (CiteScore: 8.4). #Biotech #Oncology #ADC #DrugDevelopment #SeriesC #Innovation #LifeSciences #CancerResearch #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment

🧨 We are excited to highly recommend a collection of “High-Impact Research” (review and research articles) published in Antibody Therapeutics (the official journal of our society) published within the past two years. This collection will be continuously updated with the journal's most impactful articles. Thus, you are welcome to revisit periodically the website. Free access to all these High-Impact papers via the following link. https://lnkd.in/gjmc7JC2 The ChAbS(华人抗体协会) is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. You are welcome to visit our society’s new official website: https://www.chabs.org/ Antibody Therapeutics is the official journal of ChAbs, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI (Impact Factor: 4.5), PubMed and Scopus (CiteScore: 8.4). #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics

🎉 We’re excited to celebrate a new milestone of ChAbS — 20,000 followers on our LinkedIn page! 🎉 A huge thank-you to all our Social Media Committee volunteers for their dedication and creativity 👏. As we continue to grow, we invite you to follow our society for the latest updates in antibody research, explore our official journal, Antibody Therapeutics, and join our online and onsite scientific events that bring together innovators from academia and industry 🌟 With the support of our new website below, we look forward to amplifying our impact and connecting even more with the global antibody community 🌍 www.chabs.org #AntibodyResearch #AntibodyTherapeutics #ScientificCommunity #Biotech #Growth #Networking

We’d like to share the big news that Rani Therapeutics has entered a licensing and collaboration agreement worth up to $1.09 billion with Japan's Chugai Pharmaceutical Co., Ltd. Congratulations to the team! This deal marks a major milestone for Rani, combining its groundbreaking oral biologics platform with Chugai’s innovative pipeline—opening the door to needle-free delivery of complex therapies for autoimmune and rare diseases. More information can be found here: https://lnkd.in/echGrV9g The Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI (Impact Factor: 4.5), PubMed and Scopus (CiteScore: 8.4). #biotech #healthcareinnovation #drugdelivery #rareDisease #partnerships #biologics

🧨 We’d like to recommend this excellent review article with focus upon enzymatic bioconjugation. The following is the abstract of this paper. “Enzymes have firmly established themselves as bespoke catalysts for small molecule transformations in the pharmaceutical industry, from early research and development stages to large-scale production. In principle, their exquisite selectivity and rate acceleration can also be leveraged for modifying macromolecules to form bioconjugates. However, available catalysts face stiff competition from other bioorthogonal chemistries. In this Perspective, we seek to illuminate applications of enzymatic bioconjugation in the face of an expanding palette of new drug modalities. With these applications, we wish to highlight some examples of current successes and pitfalls of using enzymes for bioconjugation along the pipeline and try to illustrate opportunities for further development.” The three authors are Aaron Debon, Elina Siirola and Radka Snajdrova at Novartis Institute For Biomedical Research. Free access to this paper: https://lnkd.in/eDcY_nEh We’d like to take this opportunity to recommend a new special collection of ADCs published in Antibody Therapeutics (Impact Factor: 4.5), an official journal of our society (see link below). https://lnkd.in/gEZ2869u #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate

🧬 Takeda has entered into a global license and collaboration agreement with Innovent Biologics to co-develop and commercialize three cutting-edge oncology programs that combine bispecific antibody and ADC innovation for solid tumors. 🔹 IBI363 – a PD-1/IL-2α-bias bispecific antibody fusion protein, designed to both block the PD-1/PD-L1 axis and selectively activate IL-2 signaling in tumor-reactive T cells. Early clinical data (>1,200 patients) show promising activity in NSCLC and MSS colorectal cancer, including PD-1/L1–refractory populations. The program has received FDA Fast Track designation for sqNSCLC. 🔹 IBI343 – a Claudin 18.2–targeted ADC using an exatecan (TOPO1i) payload, demonstrating encouraging safety and efficacy signals in gastric and pancreatic cancers — two malignancies with high unmet need. 🔹 IBI3001 (option) – an early-stage bispecific ADC targeting EGFR and B7-H3, designed for enhanced tumor selectivity and dual signaling blockade. Under the agreement: Takeda will co-develop and co-commercialize IBI363 globally (outside Greater China) with a 60/40 U.S. profit split. Takeda gains exclusive rights to IBI343 worldwide (outside Greater China). An exclusive option for IBI3001 further extends Takeda’s pipeline into novel ADC architectures. This collaboration reinforces the growing convergence of immunomodulatory bispecifics and targeted ADCs in next-generation cancer therapy, reflecting Takeda’s strategic expansion in oncology beyond 2030. The ChAbS is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics (new official website: chabs.org). Antibody Therapeutics is the official journal of ChAbS, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI (Impact Factor: 4.5), PubMed and Scopus (CiteScore: 8.4) (official website of the journal: https://lnkd.in/gVtBEqAw). #mab #antibody #antibodytherapeutics #Oncology #ADC #BispecificAntibody #ImmunoOncology #CancerTherapeutics #Biologics #DrugDevelopment #TranslationalResearch https://lnkd.in/gtSPfXdG

🚀 Join us in San Diego for mAbTalk 2025! The Chinese Antibody Society (ChAbS) and our official journal, Antibody Therapeutics, proudly present 2025 mAbTalk Symposium – “Novel Modalities in the Frontier of Antibody Therapeutics”, on Dec 14, 2025, at the Marriott Gaslamp Quarter, one day before the Antibody Engineering & Therapeutics (AET) conference. Discover the latest breakthroughs in bispecifics, ADCs, Fc engineering, oligo and peptide-antibody conjugates, and more — as leading scientists and innovators discuss how novel modalities are transforming therapeutic possibilities. 📅 Date: Dec 14, 2025 | 1–6 PM (PST) 📍 Location: San Diego, CA 🔗 Register Now at ChAbS' official website: www.chabs.org For more information https://lnkd.in/g74RVhPq #mAbTalk2025 #AntibodyTherapeutics #ChAbS #Biologics #bsAb #bispecific #AntibodyEngineering #DrugDiscovery #SanDiego #antibodydrugconjugate #antibodydrugconjugates #adc #adcs

Hansoh Bio Pharma has licensed its CDH17-targeting ADC (HS‑20110) to Roche in a global deal (ex-China) worth $80M upfront, plus milestones and royalties. 🧬 HS‑20110 is a novel ADC combining a CDH17 monoclonal antibody with a topoisomerase I inhibitor payload, currently in global Phase I trials for solid tumors, including colorectal cancer. This partnership highlights continued momentum for differentiated ADC platforms with optimized payload-linker design and tumor-selective targets like CDH17. 🔗 Read more about the deal: https://lnkd.in/eM4_AfDR The ChAbS is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics (new official website: chabs.org). Antibody Therapeutics is the official journal of ChAbS, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI (Impact Factor: 4.5), PubMed and Scopus (CiteScore: 8.4) (official website of the journal: https://lnkd.in/gVtBEqAw). #ADC #AntibodyDrugConjugate #CDH17 #HansohPharma #Roche #AntibodyPlatform #Oncology #BiopharmaDeals #PrecisionMedicine #SolidTumors

AstraZeneca and Amgen’s Tezspire, a first-in-class TSLP-targeting antibody, has received FDA approval for add-on maintenance treatment of adults and adolescents (≥12 years) with chronic rhinosinusitis with nasal polyps (CRSwNP). The approval is based on the Phase III WAYPOINT trial, where Tezspireachieved significant reductions in nasal polyp burden, near-elimination of surgery need, and lower systemic steroid use versus placebo. By blocking thymic stromal lymphopoietin (TSLP) upstream in the inflammatory cascade, Tezspire offers a novel, epithelial-driven approach to airway inflammation—extending its clinical utility beyond severe asthma. #mAb #bsAb #drugdevelopment #biologics #inflammation #FDAapproval #respiratory https://lnkd.in/gmPm9tMb